Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Arthur S. Kirsch acquired 50,000 shares of the company’s stock in a transaction on Friday, December 8th. The shares were purchased at an average cost of $1.47 per share, with a total value of $73,500.00. Following the completion of the purchase, the director now directly owns 271,609 shares of the company’s stock, valued at $399,265.23. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Aralez Pharmaceuticals Inc. (NASDAQ ARLZ) opened at $1.43 on Tuesday. The company has a quick ratio of 0.92, a current ratio of 1.00 and a debt-to-equity ratio of 4.64. Aralez Pharmaceuticals Inc. has a one year low of $0.95 and a one year high of $5.17.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.02. The company had revenue of $24.30 million during the quarter, compared to analyst estimates of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. Aralez Pharmaceuticals’s quarterly revenue was up 78.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.32) earnings per share. equities research analysts expect that Aralez Pharmaceuticals Inc. will post -1.54 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Brown Advisory Securities LLC purchased a new stake in shares of Aralez Pharmaceuticals during the third quarter valued at $394,000. Intrinsic Edge Capital Management LLC purchased a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $270,000. Ballentine Partners LLC boosted its stake in shares of Aralez Pharmaceuticals by 166.7% during the third quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock valued at $183,000 after purchasing an additional 50,000 shares during the period. GSA Capital Partners LLP boosted its stake in shares of Aralez Pharmaceuticals by 88.5% during the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock valued at $731,000 after purchasing an additional 254,400 shares during the period. Finally, Isthmus Partners LLC boosted its stake in shares of Aralez Pharmaceuticals by 0.8% during the second quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock valued at $208,000 after purchasing an additional 1,285 shares during the period. 19.60% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/12/aralez-pharmaceuticals-inc-arlz-director-purchases-73500-00-in-stock.html.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.